This trial (n=48) will follow therapists as they embark on their own psychedelic experiences. The trial’s focus is on the benefits and risks to both the therapists and the patients (and their interaction).
Topic Safety
Country Switzerland
Visit trial
Status
Not yet recruiting
Results Published
Start date
01 December 2022
End date
01 June 2029
Chance of happening
100%
Phase
Not Applicable
Design
Open
Type
Interventional
Generation
First
Participants
48
Sex
All
Age
27- 99
Therapy
No
Trial Details
The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced altered states of consciousness for physicians or psychotherapists in the context of a training course for substance-assisted therapy. Specifically, the study aims to assess changes in therapeutic attitude and other factors important in interactions between patients and therapists (such as empathy and cognitive flexibility).NCT Number
Sponsors & Collaborators
University of BaselThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.